Dehghani Mehdi, Keshavarz Pedram, Talei Abdolrasoul, Akrami Majid, Tahmasebi Sedighe, Safaie Akbar, Ghanbari Maryam
Hematology Research Center, Department of Hematology and Medical oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Radiology, Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):3027-3032. doi: 10.31557/APJCP.2020.21.10.3027.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed.
This study focuses on three groups with different pathology: group one showed complete triple-negative HER2 expression with IHC of BC; groups two and three included patients with ER-, PR-, and HER21+, and ER-, PR-, and HER22+ with a negative FISH test. These three groups were compared from the point of prognosis, which consisted of tumor size, patients' age, lymphatic, vascular and perineural invasion, organ metastasis, number of lymph nodes involvement, and the survival rate.
A total of 459 TNBC patients were enrolled, of which 268 were placed in the HER20 group, 146 in the HER21+ group, and 45 in the HER22+ group. Distant metastasis and recurrence rate were more common in HER20 patients, but bone metastasis was more common in patients with low HER2 expression. All patients with HER20 had a smaller tumor size at the time of BC diagnosis in comparison to patients in the low HER2 expression group. Patients with HER22+ had less lymphatic and vascular invasion as well as axillary lymph nodes involvement, but larger tumor size at presentation, resulting in a lower rate of recurrence and higher overall survival.
The findings revealed that patients with HER22+ had better outcome in comparison to the patients with HER20 and HER21+. Furthermore, the results showed that many patients with HER22+ expression were not basal-like and had good prognosis amongst TNBC patients.
三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌（BC），其诊断与激素受体和HER2/neu的阴性表达相关。它占所有确诊乳腺癌的10%-20%。
本研究聚焦于三组不同病理类型的患者：第一组显示乳腺癌免疫组化（IHC）中HER2完全三阴性表达；第二组和第三组包括雌激素受体（ER）、孕激素受体（PR）和HER2 1+，以及ER、PR和HER2 2+且荧光原位杂交（FISH）检测为阴性的患者。从预后角度对这三组进行比较，预后指标包括肿瘤大小、患者年龄、淋巴、血管和神经周围侵犯、器官转移、受累淋巴结数量以及生存率。
共纳入459例TNBC患者，其中268例归入HER2 0组，146例归入HER2 1+组，45例归入HER2 2+组。远处转移和复发率在HER2 0患者中更常见，但骨转移在HER2低表达患者中更常见。与HER2低表达组患者相比，所有HER2 0患者在乳腺癌诊断时肿瘤尺寸更小。HER2 2+患者的淋巴和血管侵犯以及腋窝淋巴结受累情况较少，但就诊时肿瘤尺寸更大，导致复发率较低且总生存率较高。
研究结果显示，与HER2 0和HER2 1+患者相比，HER2 2+患者预后更好。此外，结果表明许多HER2 2+表达的患者并非基底样，在TNBC患者中预后良好。
